DOCSLIB.ORG

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) National High Blood Pressure Education Program Complete Report The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute Complete Report The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure This work was supported entirely by the National Heart, Lung, and Blood Institute. The Executive Committee, writing teams, and reviewers served as volunteers without remuneration. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute National High Blood Pressure Education Program NIH Publication No. 04-5230 August 2004 Chair has received funding/grant support for research Aram V. Chobanian, M.D. (Boston University projects from Bristol-Myers Squibb, Boehringer- School of Medicine, Boston, MA) Ingelheim, Merck, Pfizer, and Pharmacia; he has served as a consultant/advisor for Abbott, Astra- Executive Committee Zeneca, Biovail, Bristol-Myers Squibb, George L. Bakris, M.D. (Rush University GlaxoSmithKline, Merck, Pfizer, and Pharmacia. Medical Center, Chicago, IL); Henry R. Black, M.D. (Rush University Medical Center, Dr. Carter has served as a consultant/advisor for Chicago, IL); William C. Cushman, M.D. Bristol-Myers Squibb. (Veterans Affairs Medical Center, Memphis, TN); Lee A. Green, M.D., M.P.H. (University Dr. Cushman has received funding/grant support of Michigan, Ann Arbor, MI); Joseph L. Izzo, for research projects from Astra-Zeneca, Merck, Jr., M.D. (State University of New York at Pfizer, Kos, Aventis Pharma, King Buffalo School of Medicine, Buffalo, NY); Pharmaceuticals, GlaxoSmithKline, and Daniel W. Jones, M.D. (University of Mississippi Boehringer-Ingelheim; he has served as a consul- Medical Center, Jackson, MS); Barry J. tant/advisor for Bristol-Myers Squibb, Sanofi, Materson, M.D., M.B.A. (University of Miami, GlaxoSmithKline, Novartis, Pfizer, Solvay, Miami, FL); Suzanne Oparil, M.D. (University Pharmacia, Takeda, Sankyo, Forest, and Biovail. of Alabama at Birmingham, Birmingham, AL); Jackson T. Wright, Jr., M.D., Ph.D. (Case Dr. Izzo has received honoraria for serving as a Western Reserve University, Cleveland, OH) speaker from Boehringer-Ingelheim, Merck, Pfizer, Astra-Zeneca, Solvay, Novartis, Forest, and Executive Secretary Sankyo; he has received funding/grant support for Edward J. Roccella, Ph.D., M.P.H. (National research projects from Boehringer-Ingelheim, Heart, Lung, and Blood Institute, Merck, Astra-Zeneca, Novartis, GlaxoSmithKline, Bethesda, MD) and Biovail; he served as a consultant/advisor for Merck, Astra-Zeneca, Novartis, Intercure, Financial Disclosures Sankyo, and Nexcura; he has stock holdings in Dr. Chobanian has received honoraria for serving Intercure, Nexcura. as a speaker from Monarch, Wyeth, Astra- Zeneca, Solvay, and Bristol-Myers Squibb. Dr. Jones has served as a consultant/advisor for Pfizer, Bristol-Myers Squibb, Merck, Forest, and Dr. Bakris has received honoraria for serving as a Novartis. speaker from Astra-Zeneca, Abbott, Alteon, Biovail, Boerhinger-Ingelheim, Bristol-Myers Dr. Manger has served as a consultant/advisor for Squibb, Forest, GlaxoSmithKline, Merck, the NHBPEP Coordinating Committee. Novartis, Sanofi, Sankyo, and Solvay; he has received funding/grant support for research pro- Dr. Materson has served as a consultant/advisor jects from National Institutes of Health, Astra- for Unimed, Merck, GlaxoSmithKline, Novartis, Zeneca, Abbott, Alteon, Boerhinger-Ingelheim, Reliant, Tanabe, Bristol-Myers Squibb, Pfizer, Forest, GlaxoSmithKline, Merck, Novartis, Pharmacia, Noven, Boehringer-Ingelheim, and Sankyo, and Solvay; he has served as a consul- Solvay. tant/advisor for Astra-Zeneca, Abbott, Alteon, Biovail, Boerhinger-Ingelheim, Bristol-Myers Dr. Oparil has received funding/grant support for Squibb, Forest, GlaxoSmithKline, Merck, research projects from Abbott Laboratories, Novartis, Sanofi, Sankyo, and Solvay. Astra-Zeneca, Aventis, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forest, Dr. Black has received honoraria for serving as a GlaxoSmithKline, Monarch, Novartis [Ciba], speaker from Astra-Zeneca, Bristol-Myers Squibb, Merck, Pfizer, Sanofi/BioClin, Schering Plough, Novartis, Pfizer, Pharmacia, and Wyeth-Ayerst; he Schwarz Pharma, Scios Inc, GD Searle, Wyeth- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure iii Ayerst, Sankyo, Solvay, and Texas Biotechnology School, Newark, NJ); Lee A. Green, M.D., Corporation; she has served as a consultant/advi- M.P.H. (University of Michigan, Ann Arbor, sor for Bristol-Myers Squibb, Merck, Pfizer, MI); Stephen Havas, M.D., M.P.H., M.S. Sanofi, Novartis, The Salt Institute, and Wyeth- (University of Maryland School of Medicine, Ayerst; she is also on the Board of Directors for Baltimore, MD); Thomas H. Hostetter, M.D. the Texas Biotechnology Corporation. (National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD); Joseph L. Dr. Sowers has received honoraria for serving as a Izzo, Jr., M.D. (State University of New York speaker from Med Com Vascular Biology at Buffalo School of Medicine, Buffalo, NY); Working Group and Joslin Clinic Foundation; he Daniel W. Jones, M.D. (University of Mississippi has received funding/grant support for research Medical Center, Jackson, MS); Lynn Kirby, projects from Novartis and Astra-Zeneca. R.N., N.P., C.O.H.N. (Sanofi-Synthelabo Research, Malvern, PA); Kathryn M. Kolasa, Dr. Wright has received honoraria for serving as a Ph.D., R.D., L.D.N. (Brody School of Medicine speaker from Astra, Aventis, Bayer, Bristol-Myers at East Carolina University, Greenville, NC); Squibb, Forest, Merck, Norvartis, Pfizer, Phoenix Stuart Linas, M.D. (University of Colorado Pharmaceuticals, GlaxoSmithKline, and Health Sciences Center, Denver, CO); William Solvay/Unimed; he has received funding/grant M. Manger, M.D., Ph.D. (New York University support for research projects from Astra, Aventis, Medical Center, New York, NY); Edwin C. Bayer, Biovail, Bristol-Myers Squibb, Forest, Marshall, O.D., M.S., M.P.H. (Indiana Merck, Norvartis, Pfizer, Phoenix University School of Optometry, Bloomington, Pharmaceuticals, GlaxoSmithKline, and IN); Barry J. Materson, M.D., M.B.A. Solvay/Unimed. (University of Miami, Miami, FL); Jay Merchant, M.H.A. (Centers for Medicare & National High Blood Pressure Education Program Medicaid Services, Washington, DC); Nancy Coordinating Committee Houston Miller, R.N., B.S.N. (Stanford Claude Lenfant, M.D. (National Heart, Lung, University School of Medicine, Palo Alto, CA); and Blood Institute, Bethesda, MD); George L. Marvin Moser, M.D. (Yale University School of Bakris, M.D. (Rush University Medical Center, Medicine, Scarsdale, NY); William A. Nickey, Chicago, IL); Henry R. Black, M.D. (Rush D.O. (Philadelphia College of Osteopathic University Medical Center, Chicago, IL); Medicine, Philadelphia, PA); Suzanne Oparil, Vicki Burt, Sc.M., R.N. (National Center for M.D. (University of Alabama at Birmingham, Health Statistics, Hyattsville, MD); Barry L. Birmingham, AL); Otelio S. Randall, M.D., Carter, Pharm.D., F.C.C.P. (University of Iowa, F.A.C.C. (Howard University Hospital, Iowa City, IA); Francis D. Chesley, Jr., M.D. Washington, DC); James W. Reed, M.D., (Agency for Healthcare Research and Quality, F.A.C.P., F.A.C.E. (Morehouse School of Rockville, MD); Jerome D. Cohen, M.D. (Saint Medicine, Atlanta, GA); Edward J. Roccella, Louis University School of Medicine, St. Louis, Ph.D., M.P.H. (National Heart, Lung, and MO); Pamela J. Colman, D.P.M. (American Blood Institute, Bethesda, MD); Lee Shaughnessy Podiatric Medical Association, Bethesda, MD); (National Stroke Association, Englewood, CO); William C. Cushman, M.D. (Veterans Affairs Sheldon G. Sheps, M.D. (Mayo Clinic, Medical Center, Memphis, TN); Mark J. Rochester, MN); David B. Snyder, R.Ph., D.D.S. Cziraky, Pharm.D., F.A.H.A. (Health Core, Inc., (Health Resources and Services Administration, Newark, DE); John J. Davis, P.A.-C. (American Rockville, MD); James R. Sowers, M.D., Academy of Physician Assistants, Memphis, F.A.C.P., F.A.C.E. (SUNY Health Science Center TN); Keith Copelin Ferdinand, M.D., F.A.C.C. at Brooklyn, Brooklyn, NY); Leonard M. (Heartbeats Life Center, New Orleans, LA); Steiner, M.S., O.D. (Eye Group, Oakhurst, NJ); Ray W. Gifford, Jr., M.D., M.S. (Cleveland Ronald Stout, M.D., M.P.H. (Procter and Clinic Foundation, Fountain Hills, AZ); Gamble, Mason, OH); Rita D. Strickland, Michael Glick, D.M.D. (New Jersey Dental Ed.D., R.N. (New York Institute of Technology, iv The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Springfield Gardens, NY); Carlos Vallbona, Vasilios Papademetriou, M.D., F.A.C.P., M.D. (Baylor College of Medicine, Houston, F.A.C.C. (Veterans Affairs Medical Center, TX); Howard S. Weiss, M.D., M.P.H. Washington, DC); Thomas G. Pickering, M.D., (Georgetown University Medical Center, D.Phil. (Mount Sinai Medical Center, New Washington Hospital Center, Walter Reed Army York, NY); Ileana L. Piña, M.D., F.A.C.C. Medical Center, Washington, DC); Jack P. (University Hospitals of Cleveland, Cleveland, Whisnant, M.D. (Mayo Clinic and Mayo OH); L. Michael Prisant, M.D., F.A.C.C., Medical School, Rochester, MN); Laurie F.A.C.P. (Medical College of Georgia, Augusta, Willshire, M.P.H., R.N. (American Red Cross, GA); Clive Rosendorff, M.D., Ph.D., F.R.C.P. Falls Church, VA); Gerald J. Wilson, M.A., (Veterans Affairs Medical Center, Bronx, NY); M.B.A. (Citizens for Public Action on Blood Virend K. Somers, M.D., Ph.D. (Mayo Clinic Pressure and Cholesterol, Inc., Potomac, MD); and Mayo Foundation, Rochester, MN); Ray Mary Winston, Ed.D., R.D. (American Heart Townsend, M.D. (University of Pennsylvania Association, Dallas, TX); Jackson T. Wright, Jr., School of Medicine, Philadelphia, PA); M.D., Ph.D. (Case Western Reserve University, Humberto Vidaillet, M.D. (Marshfield Clinic, Cleveland, OH) Marshfield, WI); Donald G.
Load more

Recommended publications
  • English Dative Alternation and Evidence for a Thematic Strategy in Adult SLA
    UCLA Issues in Applied Linguistics Title English Dative Alternation and Evidence for a Thematic Strategy in Adult SLA Permalink https://escholarship.org/uc/item/64d102q5 Journal Issues in Applied Linguistics, 5(1) ISSN 1050-4273 Author Davies, William D Publication Date 1994-06-30 DOI 10.5070/L451005171 Peer reviewed eScholarship.org Powered by the California Digital Library University of California English Dative Alternation and Evidence for a Thematic Strategy in Adult SLA William D. Davies University of Iowa INTRODUCTION A body of recent work in second language acquisition is concerned with applying constructs from Chomsky's conception of Universal Grammar in both constructing an overall theory of SLA and explaining various phenomena in L2 learners (e.g., Flynn, 1984, 1987; Hilles, 1986; Phinney, 1987; White, 1985a, 1985b; papers in Flynn and O'Neil, 1988). A key linguistic construct that has received relatively little attention in SLA research is thematic roles—notions such as AGENT, THEME, GOAL, LOCATION, SOURCE, and others that are believed to contribute to semantic encoding and decoding. Although thematic roles (alternatively, thematic relations, semantic roles, case roles, 9-roles) have long been part of modem linguistic theory (cf. Gruber, 1965; Fillmore, 1968; Jackendoff, 1972), they have enjoyed increased popularity in the recent linguistic literature owing in part to their central role in Chomsky's (1981) government and binding (GB) theory, as embodied in the G-Criterion.^ Various formulations of the 9-Criterion have been proposed, but the simple formulation in (1) will suffice here. (1) e-Criterion (Chomsky 1981, p. 36): Each argument bears one and only one H-role, and each H-role is assigned to one and only one argument.
    [Show full text]
  • PUMICE: a Multi-Modal Agent That Learns Concepts and Conditionals
    PUMICE: A Multi-Modal Agent that Learns Concepts and Conditionals from Natural Language and Demonstrations Toby Jia-Jun Li1, Marissa Radensky2, Justin Jia1, Kirielle Singarajah1, Tom M. Mitchell1, Brad A. Myers1 1Carnegie Mellon University, 2Amherst College {tobyli, tom.mitchell, bam}@cs.cmu.edu, {justinj1, ksingara}@andrew.cmu.edu, [email protected] Figure 1. Example structure of how PUMICE learns the concepts and procedures in the command “If it’s hot, order a cup of Iced Cappuccino.” The numbers indicate the order of utterances. The screenshot on the right shows the conversational interface of PUMICE. In this interactive parsing process, the agent learns how to query the current temperature, how to order any kind of drink from Starbucks, and the generalized concept of “hot” as “a temperature (of something) is greater than another temperature”. ABSTRACT CCS Concepts Natural language programming is a promising approach to •Human-centered computing ! Natural language inter­ enable end users to instruct new tasks for intelligent agents. faces; However, our formative study found that end users would of­ ten use unclear, ambiguous or vague concepts when naturally Author Keywords instructing tasks in natural language, especially when spec­ Programming by Demonstration; Natural Language Pro­ ifying conditionals. Existing systems have limited support gramming; End User Development; Multi-modal Interaction. for letting the user teach agents new concepts or explaining unclear concepts. In this paper, we describe a new multi- INTRODUCTION modal domain-independent approach that combines natural The goal of end user development (EUD) is to empower language programming and programming-by-demonstration users with little or no programming expertise to program [43].
    [Show full text]
  • Hypertension – Adult – Clinical Practice Guideline
    Hypertension – Adult – Clinical Practice Guideline Table of Contents EXECUTIVE SUMMARY ........................................................................................................... 3 SCOPE ...................................................................................................................................... 4 METHODOLOGY ...................................................................................................................... 5 INTRODUCTION ....................................................................................................................... 5 RECOMMENDATIONS .............................................................................................................. 5 Establish the Diagnosis ........................................................................................... 5 Patient Evaluation ................................................................................................... 7 Treatment Goals ..................................................................................................... 7 Lifestyle Modifications ............................................................................................. 8 Table 4 – Lifestyle Modifications ........................................................................ 9 Medication Treatment............................................................................................ 11 Figure 1 - Initiation and Titration of Antihypertensive Medication ..................... 13 Table 7 - Antihypertensive
    [Show full text]
  • The Association Between Blood Pressure Trajectories and Risk of Cardiovascular Diseases Among Non-Hypertensive Chinese Population: a Population-Based Cohort Study
    International Journal of Environmental Research and Public Health Article The Association between Blood Pressure Trajectories and Risk of Cardiovascular Diseases among Non-Hypertensive Chinese Population: A Population-Based Cohort Study Fang Li 1,2, Qian Lin 3 , Mingshu Li 3, Lizhang Chen 1,2,*,† and Yingjun Li 4,*,† 1 Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha 410078, China; [email protected] 2 Hunan Provincial Key Laboratory of Clinical Epidemiology, Changsha 410078, China 3 Department of Nutrition Science and Food Hygiene, Xiangya School of Public Health, Central South University, Changsha 410078, China; [email protected] (Q.L.); [email protected] (M.L.) 4 Department of Epidemiology and Health Statistics, School of Public Health, Hangzhou Medical College, Hangzhou 310053, China * Correspondence: [email protected] (L.C.); [email protected] (Y.L.); Tel.: +86-0731-8883-6996 (L.C.); +86-0571-8769-2815 (Y.L.) † These authors contributed equally to this work and should be considered co-correspondence authors. Abstract: Although previous studies have discussed the association between trajectories of blood pressure (BP) and risk of cardiovascular diseases (CVDs), the association among the non-hypertensive Citation: Li, F.; Lin, Q.; Li, M.; Chen, general population of youth and middle age has not been elucidated. We used the growth mixture L.; Li, Y. The Association between model to explore the trajectories of BP among the non-hypertensive Chinese population and applied Blood Pressure Trajectories and Risk Cox regression to evaluate the association between trajectories of BP and the risk of stroke or of Cardiovascular Diseases among myocardial infarction (MI).
    [Show full text]
  • High B1a0d Pressure and Its Treatment in General
    HIGH B1A0D PRESSURE AND ITS TREATMENT IN GENERAL PRACTICE WITH PARTICULAR REFERENCE TO A SERIES OF 100 CASES TREATED BY THE AUTHOR By HAROLD WILSON B01YBR IB.ffh.B. ProQuest Number: 13849841 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 13849841 Published by ProQuest LLC(2019). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 -CONTENTS SECTION 1. Introduction. SECTION 2. General Remarks. Definitions of General Interest. Present Views on Etiology. Pathology and Morbid Anatomy. Brief Historical Survey. SECTION 3. The Present Position. Prevalence. Clinical Manifestations. Prognosis. SECTION 4. Prevalence in Bolton. Summary of Cases. Symptomatology and Case Histories Prognosis. Treatment. SECTION 5. Conclusions. Bibliography. SECTION 1. INTRODUCTION. I think it can truthfully be said that the most interest­ ing problems in Medioine are those that are most baffling. Some years ago Ralph M a j o r ^ wrote these words, ”If our knowledge of the etiology of arterial hypertension is shrouded in a oertain haze, our knowledge of an effective therapy in this disease is enveloped in a dense fog.n A study of some of the vast literature on this subject does not greatly clarify the obscurity.
    [Show full text]
  • High Blood Pressure
    KNOW THE FACTS ABOUT High Blood Pressure What is high blood pressure? What are the signs and symptoms? Blood pressure is the force of blood High blood pressure usually has no against your artery walls as it circulates warning signs or symptoms, so many through your body. Blood pressure people don’t realize they have it. That’s normally rises and falls throughout the why it’s important to visit your doctor day, but it can cause health problems if regularly. Be sure to talk with your it stays high for a long time. High blood doctor about having your blood pressure pressure can lead to heart disease and checked. stroke—leading causes of death in the United States.1 How is high blood pressure diagnosed? Your doctor measures your blood Are you at risk? pressure by wrapping an inflatable cuff One in three American adults has high with a pressure gauge around your blood pressure—that’s an estimated arm to squeeze the blood vessels. Then 67 million people.2 Anyone, including he or she listens to your pulse with a children, can develop it. stethoscope while releasing air from the cuff. The gauge measures the pressure in Several factors that are beyond your the blood vessels when the heart beats control can increase your risk for high (systolic) and when it rests (diastolic). blood pressure. These include your age, sex, and race or ethnicity. But you can work to reduce your risk by How is it treated? eating a healthy diet, maintaining a If you have high blood pressure, your healthy weight, not smoking, and being doctor may prescribe medication to treat physically active.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents
    Therapeutic Class Overview Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents Therapeutic Class Overview/Summary: The renin-angiotensin-aldosterone system (RAAS) is the most important component in the homeostatic regulation of blood pressure.1,2 Excessive activity of the RAAS may lead to hypertension and disorders of fluid and electrolyte imbalance.3 Renin catalyzes the conversion of angiotensinogen to angiotensin I. Angiotensin I is then cleaved to angiotensin II by angiotensin- converting enzyme (ACE). Angiotensin II may also be generated through other pathways (angiotensin I convertase).1 Angiotensin II can increase blood pressure by direct vasoconstriction and through actions on the brain and autonomic nervous system.1,3 In addition, angiotensin II stimulates aldosterone synthesis from the adrenal cortex, leading to sodium and water reabsorption. Angiotensin II exerts other detrimental cardiovascular effects including ventricular hypertrophy, remodeling and myocyte apoptosis.1,2 The ACE inhibitors block the conversion of angiotensin I to angiotensin II, and also inhibit the breakdown of bradykinin, a potent vasodilator.4 Evidence-based guidelines recognize the important role that ACE inhibitors play in the treatment of hypertension and other cardiovascular and renal diseases. With the exception of Epaned® (enalapril solution) and Qbrelis® (lisinopril solution), all of the ACE inhibitors are available generically. Table 1. Current Medications Available in Therapeutic Class5-19 Generic Food and Drug Administration
    [Show full text]
  • Jay-Z: in Tha’ Mix
    ASC 1138--JAY-Z: IN THA’ MIX JAY-Z: IN THA’ MIX CREDIT HOURS Leta Hendricks [email protected] Tel: 614-688-7478 Classroom – Room 150A Thompson Library Class Meeting – Fridays – 1:30 – 2:18 p.m. January 11 – April 19, 2013 Office Hours – Tuesday – 9:00 – 11:00 a.m. and by appointment WEB Site – Twitter – Second Life- Hip Hop Underground http://slurl.com/secondlife/Cybrary%20City%20II/77/198/8 SYLLABUS COURSE DESCRIPTION JAY-Z is an entrepreneurial phenomenon of the last the twenty years. This seminar examines JAY-Z from different perspectives as an artist and as a businessman. The seminar will discuss perspectives and beliefs about rap music and popular culture. JAY-Z is currently one of the most influential iconic figures of Global Pop Culture. His music embodies the quintessentially “African American” genre of music, we will study his musical roots, trace the development of his career and connect JAY-Z with his culture. An analysis of his business empire will include his drug-marked youth, musical achievements, and urban-informed business savvy. The Seminar will discuss his lyrics and their meanings which reveal JAY-Z’s art and life. JAY-Z heavily borrows from American musical and literary traditions through an examination of select recordings, autobiography, film, essays and criticism, this Seminar will provide students the opportunity to discover the significance of JAY-Z’s contributions to lyric writing, popular music, and beyond. The following resources will facilitate students learning development by using multiple content formats. DJ Hero will engage students through gameplay, simulating DJ turntablism (mixing styles and techniques) connecting gaming activities to assignments, discussions, and projects on JAY-Z and current Rap artists.
    [Show full text]
  • Definiteness and Determinacy
    Linguistics and Philosophy manuscript No. (will be inserted by the editor) Definiteness and Determinacy Elizabeth Coppock · David Beaver the date of receipt and acceptance should be inserted later Abstract This paper distinguishes between definiteness and determinacy. Defi- niteness is seen as a morphological category which, in English, marks a (weak) uniqueness presupposition, while determinacy consists in denoting an individual. Definite descriptions are argued to be fundamentally predicative, presupposing uniqueness but not existence, and to acquire existential import through general type-shifting operations that apply not only to definites, but also indefinites and possessives. Through these shifts, argumental definite descriptions may become either determinate (and thus denote an individual) or indeterminate (functioning as an existential quantifier). The latter option is observed in examples like `Anna didn't give the only invited talk at the conference', which, on its indeterminate reading, implies that there is nothing in the extension of `only invited talk at the conference'. The paper also offers a resolution of the issue of whether posses- sives are inherently indefinite or definite, suggesting that, like indefinites, they do not mark definiteness lexically, but like definites, they typically yield determinate readings due to a general preference for the shifting operation that produces them. Keywords definiteness · descriptions · possessives · predicates · type-shifting We thank Dag Haug, Reinhard Muskens, Luca Crniˇc,Cleo Condoravdi, Lucas
    [Show full text]
  • 441.2.Full.Pdf
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2018-eular.4790 on 12 June 2018. Downloaded from Scientific Abstracts Thursday, 14 June 2018 441 All GCA TAK p (n 23) (n 13) (n 8) Female, n (%) 19 (82.6) 12 (92.3) 6 (75) ns Age at diagnosis 63 (51–68) 68 (63–73) 43.5 (30.5–57) 0.003 Diagnostic latency (months) 4.5 (2–12) 3 (2–10) 8 (3.5–12) ns ESR at disease onset (mm/h) 49 (38–68) 52.5 (45.5– 42 (40–61.5) ns 59.7) CRP at disease onset (mg/L) 61.8 (13– 89 (32.5–106) 60.5 (9.3–132.5) ns 132.5) Disease duration at PET/MR 27 (18–36) 24 (13–29.5) 36.5 (14.75– ns (months) 129.3) ESR at examination (mm/h) 18 (9–35) 16 (7–31) 20.5 (11–44.5) ns CRP at examination (mg/L) 4.5 (2.55–8.9) 3.9 (3.48–4.72) 4.55 (2.05–10.4) ns Results: 23 LVV patients were included, 56.5% GCA, 34.8% TAK and 8.7% iso- Results: Among 602 patients with TA during this period, 119 (19.8%) were jTA, lated aortitis, all Caucasian, mostly females (82%). We considered 55 PET scans, while 483 were aTA. Female predominance was less striking in jTA (71.4%) than 32/55 in LVV group (from min. 1 to max. 3 scans/patient) mainly during follow-up aTA (79%), p=0.047. Patients with jTA had presented more commonly with fever (29/32 scans), and 23/55 in control group.
    [Show full text]
  • Unit 10 Shock,Resuscitation Part A
    Vanderbilt University Medical Center Emergency General Surgery Service Surgical Residency Rotation and Curriculum UNIT 10SHOCK, RESUSCITATION, AND SURGICAL CRITICAL CARE PART A: SHOCK AND RESUSCITATION UNIT OBJECTIVES: 1. Demonstrate an understanding of the pathophysiology of shock and its categories. 2. Demonstrate an understanding of the mechanisms and pathophysiology of cardiopulmonary arrest. 3. Demonstrate the ability to manage the treatment of shock and cardiopulmonary arrest. COMPETENCY-BASED KNOWLEDGE OBJECTIVES: 1. Define the categories of shock based upon type, and explain the etiology and pathophysiology of each type of shock: a. Cardiogenic b. Hypovolemic c. Distributive (septic, anaphylactic, neurogenic, and adrenal insufficiency mediated) d. Obstructive (cardiac tamponade, tension pneumothorax, pulmonary embolus) 2. Summarize the clinical presentation and hemodynamic parameters associated with each type of shock. 3. Propose an algorithm for diagnosing and initiating treatment for each shock type. 4. Discuss the pathophysiology, including the mechanism of arrest, for each of the following situations: a. Acute myocardial infarction f. Substance abuse b. Acute dysrhythmia g. Hypothermia c. Congestive heart failure h. Acute stroke d. Pulmonary embolus i. Hemorrhagic shock e. Tension pneumothorax 5. Explain the indications for and the pharmacokinetics of each of the following drugs: a. Lidocaine g. Quinidine b. Bretylium h. Isoproterenol c. Digoxin i. Amiodarone d. Propanolol j. Dopamine e. Verapamil k. Dobutamine f. Pronestyl l. Adenosine (Adenocard®) 6. Summarize the indications and the appropriate techniques for cardioversion and defibrillation. Vanderbilt University Medical Center Emergency General Surgery Service Surgical Residency Rotation and Curriculum 7. Outline the signs and symptoms of acute airway obstruction and define the appropriate intervention in adult and pediatric patients.
    [Show full text]
  • 2021-2022 Student Handbook
    2021-2022 STUDENT HANDBOOK 0 TABLE OF CONTENTS School Philosophy 4 Mission Statement 4 Belief Statements 4 Profiles of Graduates 4 Read This Book 5 Affirmative Action 5 Message from the SGA President 7 Board of Education & Administrators 8 Faculty & Staff 8-9 School Calendar 10 Marking Periods/Report Card Posting 11 EMPA Exam Schedule 12 Student Rights 13-16 Smoking & Vaping 17 Alcohol and Drugs 17 PBASD Policy 17-18 Medical Aspects 18 Attendance 19-24 Philosophy Absence Procedure Absence Excuses (Non-cumulative) Emancipated Students Daily Attendance Late to School Late to Class Loss of Credit due to Excessive Absence Parent Notification Exam Attendance Cutting Class College Visitation Impact of Attendance & Extra-Curricular Activities Truancy Early Dismissal Make-up Work Religious Holidays Discipline 24-59 Philosophy Expectations for Behavior Disciplinary Options Discipline Code Weapons After-School Detention and Rules Saturday Detention Suspension Alternative Program Suspension or Expulsion Guidelines for Participation in Graduation Ceremony Off Campus Drug/Alcohol Policy Anti-Substance Abuse Agreement Intervention and Referral Service Core Team Help Lines 1 Discipline Chart Academic Integrity Policy Student Acceptable Use Policy for Technology and Internet Safety Bring IT! General Guidelines 59-74 Announcements and Bulletins Automobiles and Parking Bus Regulations Bus Evacuation Cafeteria Regulations Cell Phone Usage Communicating with the Board of Education Dress and Grooming Field Trips Fire and Safety Drills Hall Passes Health Services
    [Show full text]